DIN 02352303 — VOTRIENT 200 MG
VOTRIENT is a tablet of Pazopanib marketed by NOVARTIS PHARMACEUTICALS CANADA INC. The full Pazopanib monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02352303
- Brand name
- VOTRIENT
- Active ingredient
- Pazopanib
- Strength
- 200 MG
- Dosage form
- TABLET
- Route
- ORAL
- Manufacturer
- NOVARTIS PHARMACEUTICALS CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (antineoplastic agent)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Pazopanib products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02552957 | AURO-PAZOPANIB | 200 MG | TABLET | AURO PHARMA INC | MARKETED |
| 02525666 | PMS-PAZOPANIB | 200 MG | TABLET | PHARMASCIENCE INC | MARKETED |